Eli Lilly’s obesity pill outperforms Novo Nordisk’s oral drug in head-to-head diabetes trial
Eli Lilly said orforglipron was better at lowering blood sugar levels than Novo Nordisk's oral semaglutide, and helped patients lose more weight.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
